Table 1. Comparison of objective response rate and progression free survival of EGFR mutant T790M-positive patients receiving osimertinib post 1st/2nd generation TKIs across AURA trials (9-11).
Endpoint | AURA 1 (n=127) | AURA 2 (n=199) | AURA 3 (n=279) |
---|---|---|---|
Objective response rate | 61% | 69% | 71% |
Median PFS | 9.6 months | 9.9 months | 10.1 months |
PFS, progression free survival; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; PFS, progression free survival.